Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, FL Moving Higher; NLNK, FEYE, SWY, FCEL Lower - Alimera Sciences (NASDAQ:ALIM), Artisan Partners Asset (NYSE:APAM)

Moving up:

Skullcandy SKUL - up 23% - Reports Q4 EPS of $0.13 vs $0.09 est; revenue of $72.20M vs $71.88M est. Sees FY2014 EPS $0.10-0.14 vs $0.10 est.
dELiA*s DLIA - up 18% - 13G filing from Tiger Global on dELiA*s shows raised stake from 4.92% as of Dec. 31st to 6.3%.
Big Lots BIG - up 13% - Reports Q4 EPS from cont ops of $1.39 vs $1.42 est; revenue of $1.64B vs $1.62B est. Sees FY 2014 EPS from cont Oops $2.25-$2.45 vs $2.95 est.
GT Advanced GTAT - up 6.65% - Upgraded by Credit Suisse from Neutral to Outperform.
Cross Country Healthcare CCRN - up 6.5% - Reports Q4 loss from cont. ops. $1.14/share, sales $109.2M. Expecting Q1 sales $119-121M. Upgraded by Cantor Fitzgerald from Neutral to Buy, raises price target to $10. Upgraded by Citigroup from Neutral to Buy.
Foot Locker FL - up 6.3% - Reports Q4 EPS of $0.82 vs $0.76 est; revenue of $1.79B vs $1.76B est, comps up 5.3%.
CEL-CSI CVM - up 6.3% - Recently declared its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina via Tech Sonian.
Alimera Sciences ALIM - up 5.6% - Files to sell up to 6.25M shares at $6.85/share - S-3.
Plug Power PLUG - up 4% - May be in anticipation of CNBC appearance later this morning.
The Fresh Market TFM - up 3% - Reports Q4 EPS of $0.39 vs $0.44 est; revenue of $425.80M vs $433.31M est.
Incyte Corp INCY - up 2.8% - Announces positive top-line results from Phase III study of Ruxolitinib in patients with Polycythemia Vera.
Pixelworks PXLW - up 2.7% - Shares continue to gain after jumping 87 percent on Thursday after company reported 10 percent of sales are to Apple.

Moving down:

NewLink NLNK - down 13.8% - Company's independent review committee recommended the study continuation without modification after completion of first interim analysis of IMPRESS Phase 3 pancreatic cancer trial with algenpantucel-L.
FireEye FEYE - down 7% - Priced its follow-on public offering of 14 million shares at $82.00 per share.
Safeway SWY - down 2.7% - Agreed to be sold for $9B to private equity firm Cerberus Capital. Downgraded by BB&T Capital from Buy to Hold and removes $44 price target. Upgraded by UBS from Sell to Neutral.
FuelCell FCEL - down 2.3% - Investors taking some profits after the stock doubled from early February levels.
Artisan Partners APAM - down 1.7% - Prices 8.073M share offering at $62.00/share.
Kroger KR - down 0.8% - Misses out on Safeway deal.

Market News and Data brought to you by Benzinga APIs